Shares of Pharvaris (NASDAQ:PHVS - Get Free Report) saw an uptick in trading volume on Friday . 60,790 shares changed hands during trading, a decline of 12% from the previous session's volume of 69,045 shares.The stock last traded at $16.26 and had previously closed at $15.83.
Analyst Ratings Changes
Several research analysts have issued reports on the stock. Cantor Fitzgerald started coverage on shares of Pharvaris in a report on Tuesday. They issued an "overweight" rating and a $28.00 target price for the company. JMP Securities upped their price objective on Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a research report on Friday, January 31st.
Check Out Our Latest Analysis on Pharvaris
Pharvaris Stock Performance
The stock has a fifty day moving average of $14.96 and a 200-day moving average of $18.08. The company has a market cap of $966.32 million, a PE ratio of -6.60 and a beta of -2.84.
Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its earnings results on Monday, April 7th. The company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($0.74) by $0.06. As a group, equities analysts anticipate that Pharvaris will post -2.71 EPS for the current fiscal year.
Institutional Trading of Pharvaris
Institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. lifted its stake in shares of Pharvaris by 1,125.3% in the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock worth $59,000 after buying an additional 2,847 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Pharvaris in the 4th quarter worth approximately $64,000. Barclays PLC acquired a new position in shares of Pharvaris during the 3rd quarter worth approximately $106,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Pharvaris in the fourth quarter valued at approximately $111,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Pharvaris in the fourth quarter valued at approximately $152,000.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
See Also
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
